Evolving Data into Dollars Strategies and Accountability: Four essential elements to meet the...
-
Upload
gyles-melton -
Category
Documents
-
view
213 -
download
0
Transcript of Evolving Data into Dollars Strategies and Accountability: Four essential elements to meet the...
Evolving Data into DollarsEvolving Data into Dollars
Strategies and Accountability:
Four essential elements to meet the reality of higher-cost drugs
Oct 2012
Evolving Data into DollarsEvolving Data into Dollars
The Rationale for Benefits
Attract/ retain employees
Keep employees at work/return to work
Good corporate citizens
Balance of selfish and unselfish objectives
Evolving Data into DollarsEvolving Data into Dollars
Four Essential Elements
Innovation in plan design
Foster employee
consumerism
Challenge/lobby government
Measure and respond
Evolving Data into DollarsEvolving Data into Dollars
Innovation in design
• Why were drug benefit plans designed with a flat fee co-pay?
Evolving Data into DollarsEvolving Data into Dollars
Innovation in design
• Plan design needs to evolve to keep pace with evolving realities (escalating costs)
• Sharing of high priced drugs by insurers step in the right direction
• Need to examine ways to combine:– Flex benefits/defined contribution/healthcare spending accounts
• Pluck ideas from the US– High-deductible, account-based consumer-directed health plans
(CDHPs)
• Break the old Models– Carve out insurance for select disease categories and continue
ASO for balance
• Build exceptions into the process
Evolving Data into DollarsEvolving Data into Dollars
Employee Consumerism
Source: Harness the potential of Generation Y, http://www.sunlife.ca/static/canada/Sponsor/Bright%20papers/GenY%20BrightPaper%20E.pdf
Evolving Data into DollarsEvolving Data into Dollars
Employee Consumerism
Source: Harness the potential of Generation Y, http://www.sunlife.ca/static/canada/Sponsor/Bright%20papers/GenY%20BrightPaper%20E.pdf
Evolving Data into DollarsEvolving Data into Dollars
Employee Consumerism
• Employees need to make informed decisions about their benefits
• Need to examine ways to combine:– Flex benefits/defined contribution/healthcare spending
accounts– Elements of consumer-directed health plans (CDHPs)
• Allow accumulation and role over• Optional/non-optional insured components for high
cost disease areas• Seek tax advantaged treatment of premiums for high
cost areas (like LTD)
Evolving Data into DollarsEvolving Data into Dollars
Challenge/lobby government
• What percentage of drugs for renal cell cancer are funded by the private sector?
• Ten years ago?
Evolving Data into DollarsEvolving Data into Dollars
Challenge/lobby government
• Significant percentage of product pipeline in cancer are oral meds (1/3) and other biologics are often oral formats
• Private sector share of drug coverage increasing and will continue to do so
• Government NOT playing well with others• What can be done?
– Stop providing benefits– Dump on your employees– Live with it– Work to change the environment
Evolving Data into DollarsEvolving Data into Dollars
Challenge/lobby government
• Work to change the environment – Define government roles/accountability– Tax supportive policies– Push for trade offs– Quantify expenditures
Evolving Data into DollarsEvolving Data into Dollars
Measurement
• Considering all drugs paid for in the private sector in 2011, what are the top 3 diseases being addressed?
“While 82% of respondents agree that their company’s benefits plans provide good value … only 29% say they calculate the ROI of their
plans
Leigh Doyle | August 01, 2012
http://www.benefitscanada.com/benefits/health-benefits/justifying-the-investment-30572
• Considering all drugs paid for in the public sector in 2011, what are the top 3 diseases being addressed?
• What is the potential cost impact to the private sector of prostate cancer in 2020?
Evolving Data into DollarsEvolving Data into Dollars
Measurement
• Tools can be built to provide strategic insights in healthcare expenditures
• Challenge existing providers
• Create industry/private sector working groups to design/fund/build
• Work with the Pharmaceutical industry
• Utilize technology as an enabler
“While 82% of respondents agree that their company’s benefits plans provide good value … only 29% say they calculate the ROI of their
plans
Leigh Doyle | August 01, 2012
http://www.benefitscanada.com/benefits/health-benefits/justifying-the-investment-30572